antibodi
princip
immun
effector
mediat
protect
reinfect
follow
viral
infect
vaccin
robust
techniqu
human
mab
isol
develop
last
decad
studi
human
mab
isol
subject
prior
immun
becom
mainstay
ration
structurebas
nextgener
vaccin
develop
plethora
detail
molecular
genet
studi
coupl
structur
antigenantibodi
complex
antivir
function
begun
reveal
common
principl
critic
interact
build
better
vaccin
therapeut
antibodi
review
outlin
approach
isol
studi
human
antivir
mab
discuss
common
principl
underli
basi
activ
review
also
examin
progress
toward
goal
achiev
comprehens
understand
chemic
physic
basi
molecular
recognit
viral
surfac
protein
order
build
predict
molecular
model
use
vaccin
design
antibodi
princip
immun
effector
mediat
protect
reinfect
follow
viral
infect
vaccin
robust
techniqu
human
mab
isol
develop
last
decad
studi
human
mab
isol
subject
prior
immun
becom
mainstay
ration
structurebas
nextgener
vaccin
develop
plethora
detail
molecular
genet
studi
coupl
structur
antigenantibodi
complex
antivir
function
begun
reveal
common
principl
critic
interact
build
better
vaccin
therapeut
antibodi
review
outlin
approach
isol
studi
human
antivir
mab
discuss
common
principl
underli
basi
activ
review
also
examin
progress
toward
goal
achiev
comprehens
understand
chemic
physic
basi
molecular
recognit
viral
surfac
protein
order
build
predict
molecular
model
use
vaccin
design
method
gener
larg
amount
murin
mab
predefin
specif
first
publish
sar
milstein
georg
jf
hler
hler
milstein
nobel
prize
physiolog
medicin
advanc
laboratori
method
creation
hybridoma
cell
line
revolution
mani
field
biomed
research
includ
diagnost
gener
therapeut
antibodi
cancer
inflamm
immunotherapi
infecti
diseas
increasingli
howev
becom
appar
murin
antibodi
limit
relev
detail
type
structurefunct
studi
need
design
nextgener
human
vaccin
deepsequenc
studi
reveal
murin
antibodi
variabl
gene
repertoir
less
complex
less
divers
human
averag
length
variabl
loop
antigencombin
surfac
heavychain
complementaritydetermin
region
shorter
mice
human
shi
et
al
long
region
especi
import
mani
antivir
antibodi
respons
genet
ig
locu
experiment
anim
homolog
human
mani
case
actual
genom
sequenc
differ
significantli
case
anim
germlin
gene
segment
encod
specif
sequenc
need
bind
certain
antigen
exampl
class
hiv
neutral
antibodi
made
mous
even
monkey
specif
sequenc
human
v
h
antibodi
variabl
gene
segment
need
bind
occur
anim
navi
et
al
rhesu
macaqu
v
h
gene
segment
closest
primat
ortholog
human
v
h
gene
segment
exhibit
homolog
v
h
gene
yet
even
macaqu
v
h
allel
encod
two
three
amino
acid
human
gene
segment
defin
critic
motif
antibodi
flank
region
review
first
discuss
divers
laboratori
techniqu
isol
human
mab
assay
measur
antivir
function
antibodi
relationship
neutral
activ
protect
vivo
present
review
fundament
principl
underli
structur
genet
basi
develop
antibodi
possess
desir
featur
breadth
potenc
final
discuss
potenti
impact
grow
understand
canon
featur
protect
human
mab
ration
design
nextgener
vaccin
first
sever
decad
hybridoma
work
focus
isol
murin
mab
sever
reason
first
mice
repetit
infect
hyperimmun
foreign
antigen
increas
frequenc
antigenspecif
b
cell
second
anim
brought
necropsi
collect
spleen
b
cellrich
tissu
typic
contain
cell
contrast
typic
human
peripher
blood
sampl
research
contain
million
mononuclear
cell
million
b
cell
third
nonsecret
myeloma
fusion
partner
use
fusion
b
cell
work
well
murin
cell
human
fusion
partner
lack
eventu
investig
took
task
develop
techniqu
effici
isol
mab
human
cell
first
investig
develop
method
clone
antibodi
variabl
gene
isol
rna
follow
rtpcr
larrick
et
al
possibl
obtain
divers
amplicon
librari
variabl
gene
logic
next
step
clone
express
antibodi
phage
display
librari
express
antibodi
surfac
phage
particl
also
packag
variabl
gene
cdna
phagemid
insid
particl
kang
et
al
mccafferti
et
al
szarden
collin
learn
mani
import
principl
studi
earli
human
mab
isol
librari
includ
surpris
find
fab
alon
could
potent
inhibit
viru
replic
program
barba
et
al
crow
et
al
time
howev
becam
appar
heavyand
lightchain
pair
librari
essenti
random
investig
sought
new
method
could
isol
antibodi
singl
cell
natur
pair
heavi
light
chain
techniqu
physic
select
singl
antigenspecif
b
cell
develop
initi
method
ineffici
antigen
label
b
cell
bind
purifi
recombin
antigen
b
cell
receptor
membranebound
surfac
immunoglobulin
enabl
singlecel
flow
cytometr
sort
sort
instrument
becam
precis
sort
singl
cell
use
directli
obtain
antibodi
gene
babcook
et
al
sort
singl
cell
expand
feeder
cell
layer
follow
rna
extract
rtpcr
weitkamp
et
al
emerg
techniqu
excit
difficult
label
identifi
antigenspecif
cell
nonspecif
bind
viral
reagent
b
cell
high
set
low
frequenc
b
cell
precursor
peripher
blood
sampl
mani
donor
also
order
identifi
antibodi
bind
virion
particl
antigen
use
sort
cell
must
correct
conform
high
level
structur
fidel
form
protein
viru
featur
usual
case
solubl
form
integr
membran
protein
instanc
hundr
human
mab
identifi
use
solubl
form
dengu
envelop
protein
screen
target
demonstr
neutral
activ
smith
et
al
howev
antibodi
bound
solubl
envelop
protein
also
could
bind
live
viru
particl
immunoassay
plate
suggest
recombin
protein
alter
way
compar
virion
protein
subsequ
live
viru
particl
purifi
densiti
gradient
case
addit
immunoaffin
purifi
captur
antibodi
elisa
plate
serv
much
effect
screen
antigen
identifi
neutral
mab
anoth
method
isol
antigenspecif
human
b
cell
epsteinbarr
viru
ebv
mediat
b
cell
transform
use
activ
transform
primari
b
cell
cultur
via
ebv
receptor
b
cell
initi
howev
found
techniqu
gener
mostli
polyreact
antibodi
igm
isotyp
subsequ
addit
agonist
cpg
ebv
shown
enhanc
transform
broader
array
b
cell
bernasconi
et
al
addit
cyclosporin
inhibit
rapidli
divid
ebvspecif
cytolyt
cell
pbmc
sampl
otherwis
lyse
ebv
peptidepres
b
cell
preserv
b
cell
cultur
longer
number
import
human
mab
sar
traggiai
et
al
cmv
macagno
et
al
paramyxovirus
corti
et
al
wen
et
al
other
deriv
techniqu
transform
protocol
modifi
includ
apoptosi
inhibitor
specif
smallmolecul
inhibitor
smith
crow
use
multiprong
approach
high
effici
ebv
transform
achiev
procedur
primari
b
cell
prolifer
differenti
secret
antibodi
supernat
cell
cultur
ebvtransform
lymphoblastoid
cell
line
lcl
difficult
clone
biolog
passag
singlecel
level
howev
combin
transform
hybridoma
approach
enabl
rescu
unstabl
lcl
use
electrofus
myeloma
partner
yu
et
al
techniqu
surfac
lcl
myeloma
cell
suspens
physic
appos
use
dielectrophoresi
deliv
low
altern
current
figur
follow
direct
current
puls
caus
cell
fusion
human
hybridoma
workflow
summar
figur
result
human
hybridoma
cell
secret
mab
clone
biolog
easili
lcl
often
stop
secret
antibodi
interest
lowcelldens
cultur
limit
dilut
flow
cytometr
sort
approach
proven
exceedingli
robust
allow
isol
rare
antigenspecif
b
cell
peripher
blood
sampl
human
infect
particular
agent
decad
exposur
natur
infect
immun
exampl
human
mab
neutral
influenza
viru
isol
subject
year
age
time
virus
circul
half
centuri
yu
et
al
approach
use
isol
human
mab
dengu
viru
use
blood
usdwel
subject
previou
dengu
viru
infect
acquir
foreign
travel
decad
addit
method
human
b
cell
isol
mab
gener
continu
emerg
differ
method
activ
transform
human
b
cell
report
exampl
lentivirusmedi
transduct
memori
b
cell
two
antiapoptot
cellular
factor
bclxl
use
immort
cell
mab
discoveri
kwakkenbo
et
al
agonist
resiquimod
imidazoquinolin
compound
combin
activ
memori
b
cell
pinna
et
al
potent
stimul
ligand
activ
b
cell
b
cellactiv
factor
baff
enhanc
stabil
antibodysecret
cell
combin
factor
use
activ
maintain
b
cell
line
anoth
excit
develop
field
discoveri
antigenspecif
b
cell
circul
plasmablast
peripher
blood
circumscrib
period
follow
vaccin
day
wrammert
et
al
plasmablast
common
circul
healthi
subject
frequenc
exceed
circul
b
cell
week
vaccin
find
use
set
antigen
label
b
cell
attend
problem
nonspecif
bind
requir
instead
one
sort
circul
plasmablast
infer
specif
antigen
recent
immun
infect
method
routin
yield
interest
human
mab
howev
unclear
time
whether
domin
antibodi
clone
plasmablast
popul
persist
b
cell
memori
popul
human
final
investig
rais
concern
studi
human
b
cell
circul
may
limit
sinc
secret
antibodi
protein
circul
mediat
protect
deriv
longliv
plasma
cell
bone
marrow
studi
suggest
repertoir
bone
marrow
plasma
cell
circul
memori
b
cell
differ
purtha
et
al
variou
approach
use
address
concern
includ
mass
spectrometrybas
sequenc
antigenspecif
antibodi
protein
captur
serum
plasma
boutz
et
al
direct
studi
human
bone
marrow
specimen
measur
antivir
activ
mab
neutral
assay
antibodymedi
inhibit
virus
defin
neutral
activ
typic
measur
specif
vitro
laboratori
assay
although
vivo
challeng
studi
also
use
case
usual
live
viru
suspens
known
infecti
particl
count
mix
vari
concentr
purifi
antibodi
incub
short
period
time
mixtur
inocul
onto
cell
cultur
detect
residu
live
viru
exist
readout
percent
reduct
infecti
viru
particl
present
initi
inoculum
mani
virus
detect
use
plaqu
assay
cell
cultur
monolay
poxvirus
paramyxovirus
like
respiratori
syncyti
viru
rsv
figur
assay
format
use
increas
throughput
simplic
approach
residu
viru
follow
incub
antibodi
detect
cell
inocul
liquid
medium
allow
viru
spread
cultur
instead
use
semisolid
agar
overlay
limit
local
spread
caus
plaqu
format
liquid
overlay
assay
detect
residu
replicationcompet
viru
perform
detect
viral
antigen
chemic
substrat
use
colorimetr
optic
densiti
well
correl
amount
viral
antigen
cell
monolay
variou
type
microneutr
assay
compar
benchmark
standard
eg
influenza
assay
test
intern
partnership
consis
consortium
standard
influenza
seroepidemiolog
lauri
et
al
assay
specif
mechanist
assay
develop
studi
particular
step
viru
life
cycl
antibodi
act
instanc
potent
virusinhibit
antibodi
prevent
attach
cell
surfac
receptor
block
attach
recombin
purifi
form
cell
receptor
use
multiwel
plate
assay
format
even
viru
propag
norovirus
attach
histoblood
group
antigen
hbga
system
viruslik
particl
vlp
use
attach
purifi
hbga
antibodi
block
bind
vlp
hbga
consid
effect
neutral
noroviru
replic
convent
cultur
cell
although
recent
report
describ
replic
human
norovirus
stem
cellderiv
human
enteroid
ettayebi
et
al
principl
receptor
block
assay
surrog
neutral
also
use
hemagglutin
inhibit
virus
bind
sialic
acid
influenza
virus
sialic
acid
molecul
common
airway
epitheli
cell
also
surfac
red
blood
cell
rbc
therefor
viru
agglutin
rbc
use
surrog
viru
attach
respiratori
epitheli
cell
antibodi
block
virusmedi
agglutin
rbc
vitro
term
hemagglutinationinhibit
hai
antibodi
hai
antibodi
titer
valid
correl
protect
regulatori
agenc
releas
influenza
vaccin
us
fda
dielectrophoresi
physic
apposit
myeloma
cell
larg
human
b
cell
small
use
deliveri
altern
electr
current
caus
pearlchain
distribut
process
base
electr
principl
term
dielectrophoresi
forc
exert
particl
subject
nonuniform
electr
field
b
workflow
gener
human
mab
gener
clonal
hybridoma
cell
primari
human
b
cell
c
immunostain
larg
plaqu
top
small
plaqu
bottom
variant
rsv
use
quantit
residu
live
viru
precis
plaqu
reduct
neutral
test
variat
techniqu
includ
system
use
green
fluoresc
protein
luciferas
report
gene
approach
particularli
help
standard
use
valid
assay
standard
refer
strain
gclpcompliant
environ
done
hiv
field
tzmbl
assay
assay
system
binley
et
al
sarzottikelso
et
al
tzmbl
assay
engin
pseudovirion
display
envelop
env
interest
use
deliv
tat
gene
tzmbl
cell
grown
hela
cell
clone
engin
express
hiv
receptor
coreceptor
wei
et
al
singlecycl
infect
occur
tzmbl
cell
viral
tat
protein
induc
report
gene
express
tran
neutral
score
reduct
tatregul
firefli
luciferas
report
gene
express
activ
quantifi
rel
luminesc
unit
rlu
use
luminomet
type
assay
perform
larg
panel
refer
strain
multiwel
plate
achiev
highthroughput
capac
decamp
et
al
mascola
et
al
cell
system
similar
use
express
renilla
luciferas
report
gene
induc
express
viral
tat
protein
ci
cem
human
lcl
natur
express
receptor
coreceptor
engin
express
coreceptor
mclinden
et
al
system
engin
virus
possess
report
gene
viral
genom
use
edmond
et
al
type
system
allow
pseudotyp
report
particl
highli
pathogen
organ
mimick
biosafeti
level
bsl
laboratori
agent
typic
restrict
use
set
approach
also
allow
convent
laboratori
studi
neutral
virus
possess
live
agent
would
requir
select
agent
registr
even
perform
neutral
assay
virus
propag
permit
exampl
moratorium
use
respiratori
droplettransmiss
rdt
live
avian
influenza
viru
strain
human
mabmedi
neutral
virus
studi
use
lentivirusbas
pseudovirion
packag
hemagglutinin
ha
protein
rdt
virus
thornburg
et
al
recent
becom
appar
mani
antibodi
exhibit
neutral
activ
vitro
neutral
assay
describ
still
mediat
therapeut
protect
effect
experiment
inocul
anim
antibodi
tag
virus
virusinfect
cell
surveil
cell
immun
system
interact
cell
fragment
crystalliz
fc
region
antigenbound
antibodi
fc
region
antibodi
interact
larg
number
fc
receptor
divers
immun
cell
includ
macrophag
dendrit
cell
neutrophil
natur
killer
cell
vitro
assay
detect
cellmedi
activ
facilit
antibodi
perform
increas
precis
assay
term
antibodydepend
cellular
cytotox
adcc
assay
antibodydepend
cellmedi
viru
inhibit
adcvi
assay
other
surrog
assay
type
activ
use
fc
dimerbind
activ
beadbas
assay
group
set
techniqu
term
system
serolog
studi
term
design
reflect
comprehens
multifunct
panel
analysi
use
discoveri
philosophi
akin
system
biolog
field
high
level
interest
whether
neutral
assay
correl
protect
vivo
correl
complex
topic
definit
vivo
protect
also
complex
instanc
replic
pathogenesi
human
virus
small
anim
mice
rat
guinea
pig
may
differ
larger
anim
human
nonhuman
primat
often
prefer
anim
model
viru
replic
test
therapeut
effect
human
antibodi
even
model
perfect
mimic
human
bodi
gene
encod
receptor
epitheli
endotheli
cell
cell
immun
system
differ
extent
nonhuman
primat
human
nevertheless
case
quantit
correl
determin
vivo
protect
use
neutral
antibodi
assay
instanc
quantit
level
serum
neutral
titer
protect
lower
respiratori
tract
small
anim
challeng
rsv
determin
princ
et
al
correl
use
success
develop
test
rsv
f
proteinspecif
mab
palivizumab
mab
licens
prevent
viru
infect
sophist
vocabulari
class
correl
immun
develop
princip
plotkin
seri
paper
type
correl
heeney
plotkin
plotkin
plotkin
plotkin
plotkin
gilbert
tomara
plotkin
standard
nomenclatur
includ
term
correl
protect
cop
marker
immun
function
statist
correl
protect
vaccin
two
subtyp
cop
mechanist
correl
protect
mcop
nonmechanist
correl
protect
ncop
caus
protect
nevertheless
predict
protect
partial
correl
anoth
immun
respons
mechanist
protect
mani
laboratori
contribut
discoveri
mechan
human
antibodymedi
neutral
paper
review
field
focu
function
antibodi
discov
group
togeth
divers
group
collabor
import
quaternari
structur
one
strike
find
studi
recent
year
mani
potent
neutral
antibodi
recogn
complex
quaternari
structur
surfac
virus
would
conveni
linear
peptid
could
develop
vaccin
diagnost
epitop
understand
antibodi
respons
fact
comprehens
librari
viral
peptid
develop
librari
help
demonstr
prior
infect
xu
et
al
nevertheless
linear
peptid
rare
target
neutral
antibodi
inocul
experiment
anim
peptid
usual
induc
neutral
antibodi
therefor
long
known
neutral
determin
part
conform
natur
suspect
mani
probabl
complex
quaternari
structur
trend
toward
preferenti
quaternari
epitop
recognit
also
case
potent
human
mab
isol
mani
differ
pathogen
human
virus
exampl
dengu
envelop
protein
three
domain
protom
two
protom
form
headtotail
dimer
three
dimer
form
raft
surfac
viral
particl
kuhn
et
al
largescal
isol
human
mab
person
prior
dengu
infect
mab
sensit
detect
quaternari
featur
discov
exampl
human
mab
specif
dengu
serotyp
virus
de
alwi
et
al
recogn
bent
conform
domain
iii
region
dengu
envelop
protein
fibriansah
et
al
figur
find
interest
neutral
antibodi
bind
intact
dengu
particl
solubl
extracellular
recombin
form
dengu
serotyp
envelop
protein
angl
diii
hing
relax
visual
atom
resolut
crystal
structur
thu
conform
determin
within
one
protom
dengu
e
protein
diii
hing
essenti
recognit
type
antibodi
next
antibodi
recogn
two
protom
form
headtotailori
dimer
form
envelop
protein
dengu
viru
antibodi
shown
case
except
potent
exampl
serotyp
human
mab
de
alwi
et
al
recogn
dimer
form
envelop
surfac
particl
achiev
serotyp
specif
also
interact
diii
fibriansah
et
al
figur
interest
class
antibodi
term
envelop
dimer
epitop
ede
antibodi
bind
across
interfac
two
protom
dimer
antibodi
mediat
crossreact
bind
neutral
divers
serotyp
dengu
type
quaternari
epitop
requir
recognit
protom
within
dimer
final
class
antibodi
dengu
recogn
extrem
complex
quaternari
epitop
span
two
dimer
interact
multipl
domain
within
dimer
human
mab
exampl
type
antibodi
recogn
virion
particl
vlp
bind
recombin
envelop
protein
de
alwi
et
al
fibriansah
et
al
interestingli
antibodi
sensit
domain
iii
hing
angl
solubl
recombin
dengu
e
protein
differ
viru
structur
human
dengu
serotyp
protein
determin
crystallographi
green
base
pdb
cryoem
orang
base
emdb
particl
e
protein
maintain
bent
conform
interdomain
hing
crystal
structur
solubl
protein
achiev
linear
orient
green
b
human
mab
specif
serotyp
dengu
virus
engag
broad
surfac
envelop
protein
engag
multipl
viral
protein
domain
fab
top
heavi
chain
green
light
chain
pink
dengu
e
protein
bottom
domain
red
domain
ii
yellow
domain
iii
blue
base
pdb
c
dengu
viru
human
mab
recogn
complex
quaternari
epitop
cryoem
map
complex
fab
black
triangl
number
repres
icosahedr
asymmetr
unit
icosahedr
vertic
respect
epitop
recogn
hmab
one
molecul
fab
bind
three
e
protein
top
left
panel
show
raft
e
protein
contain
two
asymmetr
unit
three
individu
e
protein
molecul
asymmetr
unit
label
b
c
correspond
e
protein
neighbor
asymmetr
unit
b
c
di
dii
diii
color
red
yellow
blue
respect
e
enlarg
view
epitop
residu
e
protein
interact
heavi
light
chain
fab
shown
green
magenta
sphere
respect
base
pdb
cryoem
structur
dengu
viru
serotyp
complex
human
antibodi
fab
structur
determin
collabor
laboratori
sheemei
lok
conform
epitop
recogn
two
six
antigen
site
envelop
protein
raft
contain
three
dimer
thu
six
e
protein
protom
slight
conform
varieti
four
site
figur
relat
flaviviru
zika
number
neutral
human
mab
isol
subject
follow
natur
infect
recogn
divers
antigen
site
e
protein
epitop
map
alanin
scan
mutagenesi
visual
structur
antibodyviru
complex
cryoelectron
microscopi
reveal
potent
antibodi
sit
dimerdim
interfac
surfac
zika
particl
hasan
et
al
import
block
receptor
bind
physic
block
viru
bind
receptor
human
cell
one
import
common
mechan
potent
antibodymedi
viru
neutral
antibodi
recogn
receptor
bind
domain
rbd
viral
surfac
attach
protein
mediat
potent
inhibit
exampl
common
type
strongli
neutral
antibodi
influenza
viru
direct
rbd
ha
protein
antibodi
bind
near
top
surfac
head
domain
ha
protein
mediat
attach
cellular
receptor
sialic
acid
antibodi
block
receptor
bind
divers
influenza
type
virus
includ
subtyp
kraus
et
al
kraus
et
al
tsiban
et
al
xu
et
al
yu
et
al
xu
et
al
thornburg
et
al
winarski
et
al
isol
character
highresolut
crystal
structur
antibodi
complex
solubl
trimer
form
ha
recombin
ha
head
domain
proven
use
defin
chemic
physic
principl
underli
molecular
recognit
rbd
two
princip
proteinprotein
interact
identifi
canon
region
first
antibodi
present
aromat
residu
tip
one
hypervari
loop
cdr
occurr
residu
favor
aromat
amino
acid
phenylalanin
tyrosin
form
pipi
interact
aromat
residu
base
ha
rbd
molecular
mimicri
receptor
bind
occur
insert
larg
hydrophob
amino
acid
rbd
backbon
carbonyl
group
make
interact
similar
sialic
acid
carboxyl
larg
number
antibodi
describ
featur
exampl
shown
figur
see
also
lee
wilson
second
residu
tip
antibodi
cdr
proven
facilit
interact
ha
rbd
aspart
residu
interact
favor
charg
interact
ha
protein
carboxyl
acid
properli
posit
aspart
acid
cdr
mimic
carboxyl
sialic
acid
backbon
atom
mimic
acetamido
group
receptor
larg
number
antibodi
residu
identifi
visual
highresolut
structur
achiev
import
critic
interact
figur
see
also
hong
et
al
schmidt
et
al
whittl
et
al
wu
wilson
interestingli
although
present
aspart
residu
posit
seem
rule
satisfi
interact
neutral
human
antibodi
design
aspart
right
posit
loop
use
aspart
interact
canon
fashion
thornburg
et
al
winarski
et
al
figur
thu
although
structur
rule
engag
antibodi
identifi
structur
featur
simpli
short
sequenc
singl
residu
rather
element
function
predict
proper
context
interestingli
antibodi
select
phagedisplay
librari
human
b
cell
variabl
gene
possess
aromat
aspart
residu
proper
posit
bind
ha
rbd
mimicri
sialic
acid
bind
lee
et
al
crystal
structur
complex
divers
virus
reveal
structur
basi
neutral
breadth
insert
rbd
allow
mimic
sialic
acid
high
degre
lee
et
al
carboxyl
side
chain
antibodi
close
align
carboxyl
sialic
acid
would
found
posit
use
network
hydrogen
bond
bind
ha
creat
addit
hydrogen
bond
fab
main
chain
use
interact
residu
ha
one
challeng
neutral
influenza
rbd
high
level
variabl
amino
acid
sequenc
surround
rim
amino
acid
encompass
approach
recess
rbd
see
http
wwwfludborg
antibodi
interact
residu
ha
head
vari
circul
field
strain
antibodi
like
subtyp
specif
even
strain
specif
variabl
underli
much
antigen
drift
occur
season
season
influenza
virus
one
engin
principl
could
use
effici
neutral
would
design
biolog
antibodi
interact
base
rbd
bind
variabl
rim
rbd
one
interest
broadli
neutral
antibodi
except
long
design
essenti
achiev
interact
focus
mostli
base
rbd
figur
understood
time
rare
antibodi
point
way
possibl
path
ration
design
new
broadli
neutral
therapeut
loop
possess
intern
selfstabil
hydrogen
bond
interact
similar
bhairpin
provid
extens
hydrogen
bond
interact
backbon
atom
loop
ha
interest
approach
explor
use
stabl
loop
miniantibodi
eg
use
comput
design
trimer
protein
mimick
engag
ha
rbd
strauch
et
al
begin
learn
potent
neutral
antibodi
often
use
canon
mode
interact
cross
viru
famili
reason
think
chemic
physic
determin
bind
viral
protein
aromat
aspart
residu
discuss
would
specif
one
viru
protein
howev
domin
role
aromat
residu
mediat
antibodi
variabl
loop
rbd
also
proven
highli
pertin
filoviru
antibodi
filovirus
marburg
ebola
virus
bind
niemannpick
diseas
type
protein
receptor
endosom
virus
attach
receptor
use
rbd
surfac
glycoprotein
gp
human
mab
isol
singl
survivor
natur
marburg
infect
found
neutral
antibodi
compet
bind
gp
region
found
rbd
structur
complex
determin
interestingli
singleparticl
em
reconstruct
studi
panel
antibodi
show
could
approach
rbd
vari
angl
bind
pose
interact
arriv
common
final
solut
place
cdr
loop
rbd
atom
resolut
structur
one
antibodi
marburg
ebola
gp
show
cdr
loop
present
aromat
residu
establish
pipi
relationship
aromat
residu
bottom
rbd
essenti
design
principl
discuss
influenzaneutr
antibodi
isol
marburg
mab
interact
rbd
uncleav
ebola
gp
one
antibodi
design
recogn
ebola
gp
even
presenc
ebola
glycan
cap
partial
shield
ebola
rbd
base
canon
mode
interact
aromat
residu
capac
bind
ebola
gp
bispecif
antibodi
compris
marburg
fab
anoth
antibodi
receptor
ebola
gp
glycan
cap
use
deliv
construct
cell
endosom
cell
compart
marburg
antibodi
could
recogn
rbd
cleav
ebola
gp
protect
viral
glycan
cap
prior
cleavag
neutral
ebola
viru
wec
et
al
even
remark
threeway
structur
mimicri
interact
use
principl
describ
ebola
viru
glycan
cap
surfac
gp
protect
rbd
ebola
viru
exposur
endosom
use
aromat
residu
interact
aromat
amino
acid
gp
rbd
way
human
mab
recent
gao
colleagu
show
viru
interact
receptor
use
principl
employ
aromaticrich
interfac
figur
unusu
demonstr
f
crystal
structur
broadli
neutral
antibodi
bound
influenza
hemagglutinin
subunit
antibodi
fab
yellow
structur
right
engag
rbd
influenza
ha
protein
red
structur
left
princip
singl
cdr
base
pdb
structur
determin
laboratori
ian
wilson
ben
spiller
threeway
structur
mimicri
type
biolog
case
viral
protein
human
antibodi
human
receptor
use
type
interact
residu
engag
rbd
viral
protein
strong
desir
field
immunotherapeut
identifi
highli
conserv
epitop
antigen
site
target
antibodi
use
vaccin
antigen
idea
spur
broad
search
vaccin
antigen
induc
broad
crossreact
univers
antibodi
exampl
antibodi
equal
recogn
rsv
fusion
protein
antigen
subgroup
b
discov
antibodi
recogn
either
prefus
postfus
barba
et
al
crow
et
al
form
protein
also
exist
principl
well
develop
influenza
vaccin
design
field
sever
group
identifi
human
mab
neutral
virus
one
subtyp
influenza
virus
block
rbd
word
hai
activ
ekiert
et
al
sui
et
al
throsbi
et
al
crystal
structur
haantibodi
complex
reveal
antibodi
interact
stem
domain
influenza
ha
protein
much
conserv
head
domain
even
interest
mani
stembind
antibodi
found
canon
mode
interact
heavi
chain
interact
hydrophob
depress
stem
protein
domain
antibodi
encod
singl
heavychain
variabl
region
design
v
h
germlin
gene
segment
encod
hydrophob
cdr
sinc
initi
discoveri
mab
becom
appar
human
b
cell
encod
type
antibodi
subsequ
addit
complex
interact
stem
identifi
even
broader
antibodi
recogn
virus
differ
major
phylogenet
group
corti
et
al
addit
v
h
gene
encod
stem
antibodi
identifi
even
v
h
antibodi
somat
mutat
antibodi
lineag
achiev
novel
somewhat
noncanon
interact
region
pappa
et
al
sever
antibodi
test
experiment
therapeut
human
broad
antiinfluenza
activ
comput
design
small
protein
mimic
stem
antibodi
also
report
fleishman
et
al
koday
et
al
principl
exploit
antibodi
develop
also
engin
antigen
view
use
vaccin
induc
type
antibodi
field
develop
univers
flu
vaccin
antigen
progress
made
proofofprincipl
studi
difficult
faith
recapitul
conform
ha
stem
simpli
truncat
protein
term
headless
protein
approach
steel
et
al
complex
engin
protocol
stabil
stem
vaccin
pursu
current
recent
investig
develop
chimer
ha
protein
present
conserv
stem
region
influenza
type
b
virus
molecul
contain
avian
influenza
ha
head
domain
immun
common
human
popul
ermler
et
al
hai
et
al
rational
preexist
human
memori
b
cell
recogn
conserv
epitop
stem
boost
memori
respons
chimer
protein
primari
b
cell
respons
head
domain
less
signific
compon
respons
target
stem
region
surfac
gp
conserv
sequenc
head
domain
also
proven
use
approach
find
broadli
neutral
antibodi
viral
gp
glycan
cap
human
protein
filoviru
receptor
human
mab
use
aromaticrich
loop
bind
base
wang
et
al
virus
influenza
entir
enterpris
develop
studi
hiv
antibodi
region
hiv
design
membraneproxim
extern
region
mper
broad
potent
neutral
antibodi
muster
et
al
huang
et
al
other
studi
great
detail
antibodi
appear
autoreact
properti
like
due
interact
antibodi
lipid
moieti
membran
virus
virusinfect
cell
mper
antibodi
also
describ
filovirus
excit
exhibit
breadth
neutral
divers
speci
ebola
virus
bornholdt
et
al
flyak
et
al
given
natur
occur
human
antibodi
recogn
antigen
divers
strain
particular
viru
isol
natur
explor
whether
individu
mab
could
found
crossreact
differ
virus
within
viru
famili
increasingli
see
broad
molecular
recognit
possibl
exampl
human
mab
neutral
poxvirus
commonli
pathogen
human
includ
variola
smallpox
monkeypox
cowpox
vaccinia
smallpox
vaccin
virus
isol
gilchuk
et
al
type
crossreact
antibodi
found
within
respons
direct
one
mani
differ
viru
protein
two
major
structur
distinct
form
poxvirus
matur
virion
mv
envelop
virion
ev
mab
isol
human
prior
chikungunya
viru
infect
includ
mab
recogn
major
pathogen
alphavirus
fox
et
al
antibodi
crossreact
fusion
protein
two
divers
paramyxovirus
rsv
human
metapneumoviru
caus
pediatr
pneumonia
wheez
report
corti
et
al
wen
et
al
long
known
antibodi
fusion
loop
antigen
site
flaviviru
e
protein
crossreact
flavivirus
fact
antibodi
enhanc
viru
replic
second
heterolog
infect
term
antibodydepend
enhanc
ade
howev
also
possibl
identifi
human
mab
neutral
divers
flavirus
dengu
zika
barbaspaeth
et
al
although
studi
structur
basi
viru
neutral
human
antibodi
de
facto
requir
use
mab
import
realiz
type
studi
allow
snapshot
respons
happen
vivo
enough
antibodi
obtain
singl
individu
singl
agent
becom
clear
case
human
b
cell
respons
recogn
virtual
everi
amino
acid
surfac
viral
protein
exampl
mab
chikungunya
singl
individu
map
satur
alanin
scan
mutagenesi
decor
nearli
entir
surfac
domain
viru
figur
polyclon
respons
benefici
divers
antibodi
clone
exhibit
cooper
effect
neutral
protect
exampl
optim
protect
poxvirus
vivo
minim
requir
cooper
mixtur
mab
complex
neutral
two
form
virion
particl
use
multipl
redund
adhes
factor
form
particl
gilchuk
et
al
hand
nonneutr
mab
compet
bind
site
rsv
f
protein
recogn
licens
neutral
mab
palivizumab
also
report
mousa
et
al
principl
antibodi
could
inhibit
protect
effect
therapeut
antibodi
thu
futur
research
field
includ
studi
understand
complex
biolog
mixtur
antibodi
techniqu
studi
genet
antibodi
variabl
gene
encod
antibodi
becom
increasingli
sophist
discuss
possibl
obtain
analyz
genet
sequenc
encod
mab
singl
b
cell
mab
techniqu
use
convent
sanger
sequenc
sinc
late
recent
largescal
nextgener
sequenc
antibodi
variabl
gene
repertoir
first
report
zebrafish
weinstein
et
al
appli
human
sampl
allow
sequenc
million
even
billion
variabl
gene
sequenc
human
blood
sampl
descript
studi
use
deep
sequenc
reveal
interest
featur
antibodi
repertoir
includ
common
origin
long
antibodi
naiv
b
cell
h
recombin
long
naddit
region
briney
et
al
hotspot
region
insert
delet
somat
hypermut
briney
et
al
rel
high
frequenc
v
h
dd
j
h
recombin
human
peripher
blood
antibodi
repertoir
briney
et
al
tissuespecif
featur
antibodi
repertoir
briney
et
al
coupl
singl
b
cell
techniqu
antigenspecif
mab
discoveri
nextgener
sequenc
antibodi
variabl
gene
repertoir
locat
residu
requir
mab
bind
map
alanin
scan
mutagenesi
antibodi
shown
map
onto
crystal
structur
matur
envelop
glycoprotein
complex
pdb
side
view
ribbon
trace
singl
heterodim
shown
light
cyan
domain
color
side
chain
amino
acid
requir
mab
bind
shown
spacefil
form
individu
color
code
individu
antibodi
residu
bound
one
antibodi
indic
vari
shade
gray
base
subject
began
allow
us
identifi
antibodi
clonal
lineag
diversifi
somat
hypermut
kraus
et
al
immedi
becam
appar
antibodi
clone
diversifi
robust
introduct
somat
mutat
within
lineag
intraclon
diversif
also
independ
genet
distinct
germlineencod
b
cell
clone
direct
common
epitop
converg
common
contact
residu
somat
hypermut
kraus
et
al
studi
identifi
specif
variabl
gene
protein
motif
associ
specif
instanc
five
differ
human
mab
identifi
singl
individu
influenza
ha
encod
singl
v
h
gene
v
h
kraus
et
al
deep
sequenc
identifi
sibl
antibodi
person
immun
repertoir
type
v
h
associ
describ
influenza
ha
stem
antibodi
discuss
v
h
v
h
hiv
antibodi
field
entir
class
antibodi
design
class
antibodi
typic
encod
v
h
allel
find
particularli
import
explain
human
readili
make
antibodi
experiment
anim
like
mice
macaqu
essenti
germlin
gene
encod
homolog
antibodi
model
anim
bind
bind
site
larger
larger
number
antibodi
made
common
sequenc
seen
across
individu
could
term
public
clonotyp
use
vocabulari
similar
use
studi
cell
exampl
potent
neutral
antibodi
design
recogn
diii
zikv
e
protein
describ
recent
subsequ
similar
antibodi
also
encod
v
h
j
h
variabl
gene
segment
individu
report
robbiani
et
al
time
expect
abl
routin
assign
specif
mani
antibodi
base
sequenc
even
excit
comput
method
predict
structur
antibodi
use
sequenc
emerg
exampl
rosetta
model
softwar
suit
use
redesign
broadli
neutral
human
hivspecif
mab
increas
potenc
breadth
singl
amino
acid
chang
increas
thermal
stabil
without
alter
contact
residu
convert
mode
bind
glycan
independ
willi
et
al
type
structur
predict
coupl
novel
positionspecif
structurebas
score
matrix
enabl
deepsequenc
search
antibodi
repertoir
hivnaiv
subject
find
antibodi
bind
neutral
hiv
willi
et
al
predict
techniqu
determinist
rel
ineffici
present
see
time
futur
antibodi
discoveri
could
done
simpli
explor
antibodi
sequenc
databas
technolog
field
repertoir
sequenc
evolv
rapidli
allow
ever
deeper
sequenc
fact
project
sequenc
b
cell
receptor
human
popul
effort
term
human
immunom
program
initi
crow
koff
understand
rule
engag
protect
antibodi
begin
help
guid
structurebas
vaccin
design
revers
vaccinolog
central
rational
approach
broadli
protect
potent
antibodi
natur
occur
human
reveal
antigen
site
epitop
could
serv
compon
prevent
vaccin
induc
type
antibodi
proofofprincipl
approach
first
shown
use
epitop
licens
antirsv
antibodi
palivizumab
term
antigen
site
ii
correia
et
al
comput
design
ahel
protein
scaffold
present
correct
conform
minim
palivizumab
epitop
small
helixloophelix
structur
discov
structur
induc
neutral
antibodi
epitop
bound
similar
manner
palivizumab
correia
et
al
progress
made
similar
approach
hiv
vaccin
design
base
epitop
broad
potent
hivneutr
antibodi
escolano
et
al
steichen
et
al
tian
et
al
major
technic
advanc
recent
year
isol
human
mab
virus
care
studi
neutral
antibodymedi
antivir
function
reveal
human
make
divers
potent
antibodi
virtual
pathogen
organ
em
crystallographi
studi
antigenantibodi
complex
begun
elucid
structur
basi
molecular
recognit
virus
establish
canon
mode
interact
deep
sequenc
antibodi
variabl
gene
repertoir
show
tremend
complex
human
b
cell
respons
begin
synthes
divers
type
inform
goal
accomplish
ration
develop
new
vaccin
revers
vaccinolog
principl
structurebas
design
seem
increasingli
realist
